Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Mycophenolate sodium (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 04 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2024 Planned End Date changed from 30 Aug 2024 to 31 Jul 2025.
- 12 Jun 2024 Planned primary completion date changed from 30 Aug 2024 to 31 Jul 2025.